NCT02840708View on ClinicalTrials.gov

SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

September 1, 2017

Conditions
Pulmonary Alveolar Proteinosis, Autoimmune
Interventions
DRUG

Sargramostim

Trial Locations (1)

Unknown

Niigata University Med & Dental Hospital, Niigata

All Listed Sponsors
lead

Niigata University Medical & Dental Hospital

OTHER

NCT02840708 - SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study | Biotech Hunter | Biotech Hunter